WebDisclosure WebDisclosure
Basculer en Français
11289 Companies
250816 Keywords
179572 Articles
136626 Press releases
Headlines Articles Press releases Systasy Bioscience GmbH Remove
  1. Home
  2. Companies
  3. Systasy Bioscience GmbH
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 07/31/2024 at 09:05, 2 years 3 months ago

    Systasy Bioscience Announces Collaboration Agreement with Ono Pharmaceutical

    Drug Discovery Neurological Disorders Collaboration Agreement Systasy Bioscience Ono Pharmaceutical
  • BRIEF

    published on 07/31/2024 at 09:05, 2 years 3 months ago

    Systasy Bioscience annonce un accord de collaboration avec Ono Pharmaceutical

    Découverte De Médicament Troubles Neurologiques Accord De Collaboration Systasy Biosciences Ono Pharmaceutique
  • PRESS RELEASE

    published on 07/31/2024 at 09:00, 2 years 3 months ago

    Systasy Bioscience Announces Collaboration Agreement with Ono Pharmaceutical

    Systasy Bioscience GmbH announces collaboration agreement with Ono Pharmaceutical for new therapeutic targets in neurological disorders. Partnership aims at advancing drug discovery for complex mental disorders
    Drug Discovery Neurological Disorders Collaboration Agreement Systasy Bioscience Ono Pharmaceutical
    Logo of Systasy Bioscience GmbH
Accesswire
  • Published on 11/05/2026 at 15:20, 2 hours 46 minutes ago

    MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors

  • Published on 11/05/2026 at 14:31, 3 hours 35 minutes ago

    First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile

  • Published on 11/05/2026 at 14:25, 3 hours 41 minutes ago

    Polaris Renewable Energy Announces Q3 2026 Results

  • Published on 11/05/2026 at 14:20, 3 hours 46 minutes ago

    Polaris Renewable Energy Declares Quarterly Dividend

  • Published on 11/05/2026 at 14:15, 3 hours 51 minutes ago

    Loar Holdings Inc. Reports Q3 2026 Record Results and Upward Revision to 2026 Outlook and Full Year 2027 Outlook

View all ACCESSWIRE
EQS Group
  • Published on 11/05/2026 at 17:45, 21 minutes ago

    MEDACTA GROUP SA UPDATES GUIDANCE FOR 2026 AND REITERATES 2024-2027 MID-TERM OUTLOOK

  • Published on 11/05/2026 at 16:45, 1 hour 21 minutes ago

    Ondo Finance Becomes World's Largest Tokenization Platform

  • Published on 11/05/2026 at 15:55, 2 hours 11 minutes ago

    Cairn Homes Plc: Holding(s) in Company

  • Published on 11/05/2026 at 15:34, 2 hours 31 minutes ago

    Finexity AG: NuWays and GBC confirm price targets following Capital Markets Day and 9-month figures, taking the share split into account

  • Published on 11/05/2026 at 15:10, 2 hours 56 minutes ago

    Center for Creative Leadership Names Patrick Mullane President and Chief Executive Officer

View all EQS
Les Echos
  • Published on 11/05/2026 at 17:50, 16 minutes ago

    NRJ GROUP - Financial information Q3 2026

  • Published on 11/05/2026 at 17:50, 16 minutes ago

    NRJ GROUP - Information financière T3 2026

  • Published on 11/05/2026 at 17:45, 21 minutes ago

    INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

  • Published on 11/05/2026 at 17:45, 21 minutes ago

    MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

  • Published on 11/05/2026 at 17:45, 21 minutes ago

    Informations relatives au nombre total de droits de vote et d’actions

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy